Photo of Theodore S. Hong,  MD

Theodore S. Hong, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-1159
Fax: (617) 726-3603


tshong1@partners.org

Theodore S. Hong, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Radiation Oncology, Harvard Medical School
  • Director, Gastrointestinal Service, Radiation Oncology, Massachusetts General Hospital
  • Associate Clinical Director, Radiation Oncology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

As Director of Gastrointestinal Radiation Oncology and co-Director of the Tucker Gosnell Center for Gastrointestinal Cancers at MGH, I am integrately involved in patient care and clinical research. My research involves clinical trials with advanced radiation and integration with targeted therapies. I collaborate closely with basic scientists to bring new agents to clinical trial. Additionally, I am interested in biomarkers that predict outcomes to radiation or chemoradiation.

Publications

Powered by Harvard Catalyst
  • Liu Q, Underwood TS, Kung J, Wang M, Lu HM, Paganetti H, Held KD, Hong TS, Efstathiou JA, Willers H. Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation. Int J Radiat Oncol Biol Phys 2016; 95:78-85. PubMed
  • Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT. The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality. J Surg Oncol 2016; 113:560-4. PubMed
  • Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, Hong TS, Kwak EL, Lauwers GY. A protein and mRNA expression-based classification of gastric cancer. Mod Pathol 2016. PubMed
  • Rose BS, Jee KW, Niemierko A, Murphy JE, Blaszkowsky LS, Allen JN, Lee LK, Wang Y, Drapek LC, Hong TS, Wo JY. Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation. Int J Radiat Oncol Biol Phys 2016; 94:747-54. PubMed
  • Muralidhar V, Nipp RD, Ryan DP, Hong TS, Nguyen PL, Wo JY. Association Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer. Dis Colon Rectum 2016; 59:187-93. PubMed
  • Kamran SC, Hong TS, Wo JY. Advances in the Management of Gastric and Gastroesophageal Cancers. Curr Oncol Rep 2016; 18:13. PubMed
  • Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 2015. PubMed
  • Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A, Corcoran RB. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. 2015. PubMed
  • Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Godfrey JT, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. 2015; 5:1271-81. PubMed
  • Ferreiro-Neira I, Torres N, Liesenfeld L, Chan CH, Penson T, Landesman Y, Senapedis W, Shacham S, Hong TS, Cusack JC. XPO1 inhibition enhances radiation response in preclinical models of rectal cancer. Clin Cancer Res 2015. PubMed
  • Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol 2015. PubMed
  • Russo S, Blackstock AW, Herman JM, Abdel-Wahab M, Azad N, Das P, Goodman KA, Hong TS, Jabbour SK, Jones WE, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M, Small W, Thomas CR, Suh WW. ACR Appropriateness Criteria® Local Excision in Early Stage Rectal Cancer. Am J Clin Oncol 2015; 38:520-5. PubMed
  • Setia N, Clark JW, Duda DG, Hong TS, Kwak EL, Mullen JT, Lauwers GY. Familial Gastric Cancers. Oncologist 2015. PubMed
  • Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT. Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach. J Gastrointest Surg 2015. PubMed
  • Ahmad R, Setia N, Schmidt BH, Hong TS, Wo JY, Kwak EL, Rattner DW, Lauwers GY, Mullen JT. Predictors of Lymph Node Metastasis in Western Early Gastric Cancer. J Gastrointest Surg 2015. PubMed
  • Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A, Zhu AX, Goyal L, Ting DT, Bardeesy N, Hong TS, Fernandez-Del Castillo C, Tanabe KK, Lillemoe KD, Ferrone S, Ferrone CR. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res 2015. PubMed
  • Hong TS, Moughan J, Garofalo MC, Bendell J, Berger AC, Oldenburg NB, Anne PR, Perera F, Lee RJ, Jabbour SK, Nowlan A, DeNittis A, Crane C. NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 2015. PubMed
  • Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist 2015; 20:1019-27. PubMed
  • Niska JR, Keane FK, Wolfgang JA, Hahn PF, Wo JY, Zhu AX, Hong TS. Impact of intravenous contrast enhancement phase on target definition for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC): Observations from patients enrolled on a prospective phase 2 trial. 2015. PubMed
  • Wu AJ, Bosch WR, Chang DT, Hong TS, Jabbour SK, Kleinberg LR, Mamon HJ, Thomas CR, Goodman KA. Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. Int J Radiat Oncol Biol Phys 2015; 92:911-20. PubMed
  • Hong TS, Ryan DP. Adjuvant Chemotherapy for Locally Advanced Rectal Cancer: Is It a Given? J Clin Oncol 2015; 33:1878-80. PubMed
  • Liu Q, Wang M, Kern AM, Khaled S, Han J, Yeap BY, Hong TS, Settleman J, Benes CH, Held KD, Efstathiou JA, Willers H. Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers. Mol Cancer Res 2015. PubMed
  • Willers H, Hong TS. Towards an integrated understanding of epidermal growth factor receptor biology for radiation therapy: integrins enter. Journal of the National Cancer Institute 2015. PubMed
  • Kulkarni NM, Hong TS, Kambadakone A, Arellano RS. CT-guided implantation of intrahepatic fiducial markers for proton beam therapy of liver lesions: assessment of success rate and complications. AJR Am J Roentgenol 2015; 204:W207-13. PubMed
  • Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015; 261:12-7. PubMed
  • Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371:2140-1. PubMed
  • Mirabeau-Beale K, Hong TS, Niemierko A, Ancukiewicz M, Blaszkowsky LS, Crowley EM, Cusack JC, Drapek LC, Kovalchuk N, Markowski M, Napolitano B, Nyamwanda J, Ryan DP, Wolfgang J, Kachnic LA, Wo JY. Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. 2015. PubMed
  • Goodman KA, Milgrom SA, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Hong TS, Jabbour SK, Jones WE, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M, Small W, Thomas CR, Suh WW, . ACR Appropriateness Criteria® rectal cancer: metastatic disease at presentation. Oncology (Huntingt) 2014; 28:867-71, 876, 878. PubMed
  • Hong TS, Kwak EL. Adjuvant therapy for gastric cancers: more answers or more questions? Ann Surg Oncol 2014. PubMed
  • Richter JM, Pino MS, Austin TR, Campbell E, Szymonifka J, Russo AL, Hong TS, Borger D, Iafrate AJ, Chung DC. Genetic mechanisms in interval colon cancers. Dig Dis Sci 2014. PubMed
  • Tanguturi SK, Wo JY, Zhu AX, Dawson LA, Hong TS. Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist 2014; 19:868-79. PubMed
  • Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys 2014. PubMed
  • Hong TS, Bosch WR, Krishnan S, Kim TK, Mamon HJ, Shyn P, Ben-Josef E, Seong J, Haddock MG, Cheng JC, Feng MU, Stephans KL, Roberge D, Crane C, Dawson LA. Interobserver variability in target definition for hepatocellular carcinoma with and without portal vein thrombus: radiation therapy oncology group consensus guidelines. Int J Radiat Oncol Biol Phys 2014; 89:804-13. PubMed
  • Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer 2014. PubMed
  • Patel SA, Chen YH, Hornick JL, Catalano P, Nowak JA, Zukerberg LR, Bleday R, Shellito PC, Hong TS, Mamon HJ. Early-stage rectal cancer: clinical and pathologic prognostic markers of time to local recurrence and overall survival after resection. Dis Colon Rectum 2014; 57:449-59. PubMed
  • Chin JY, Pitman MB, Hong TS. Intraductal papillary mucinous neoplasm: clinical surveillance and management decisions. Semin Radiat Oncol 2014; 24:77-84. PubMed
  • Wo JY, Dawson LA, Zhu AX, Hong TS. An emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 2014; 23:353-68. PubMed
  • Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res 2014; 20:1884-90. PubMed
  • Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J Gastrointest Cancer 2014; 45:34-9. PubMed
  • Schoenfeld JD, Wo JY, Mamon HJ, Kwak EL, Mullen JT, Enzinger PZ, Blaskowsky LS, Ryan DP, Hong TS. The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation. Am J Clin Oncol 2014. PubMed
  • Wo JY, Mamon HJ, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Tseng YD, Napolitano BN, Ancukiewicz M, Swanson RS, Lillemoe KD, Fernandez-del Castillo C, Hong TS. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiother Oncol 2014; 110:160-4. PubMed
  • Kim MB, Hong TS, Wo JY. Treatment of stage II-III rectal cancer patients. Curr Oncol Rep 2013; 16:362. PubMed
  • , Hong TS, Pretz JL, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Goodman KA, Jabbour SK, Jones WE, Konski AA, Koong AC, Rodriguez-Bigas M, Small W, Thomas CR, Zook J, Suh WW. ACR Appropriateness Criteria®-Anal Cancer. Gastrointest Cancer Res 2014; 7:4-14. PubMed
  • Cai S, Hong TS, Goldberg SI, Fernandez-del Castillo C, Thayer SP, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Willett CG, Lillemoe KD, Warshaw AL, Wo JY. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer 2013; 119:4196-204. PubMed
  • Schmidt B, Look-Hong N, Maduekwe UN, Chang K, Hong TS, Kwak EL, Lauwers GY, Rattner DW, Mullen JT, Yoon SS. Noncurative gastrectomy for gastric adenocarcinoma should only be performed in highly selected patients. Ann Surg Oncol 2013; 20:3512-8. PubMed
  • Pretz JL, Wo JY, Mamon HJ, Kachnic LA, Hong TS. Chemoradiation therapy: localized esophageal, gastric, and pancreatic cancer. Surg Oncol Clin N Am 2013; 22:511-24. PubMed
  • Hong TS. Radiotherapy for hepatocellular carcinoma with tumor vascular thrombus: ready for prime time? J Clin Oncol 2013. PubMed
  • Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V, Hong TS, Kwak EL, Lauwers GY, Ryan DP, Wargo JA, Lillemoe KD, Ferrone CR. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg 2013. PubMed
  • Yuan Y, Andronesi OC, Bortfeld TR, Richter C, Wolf R, Guimaraes AR, Hong TS, Seco J. Feasibility study of in vivo MRI based dosimetric verification of proton end-of-range for liver cancer patients. Radiother Oncol 2013; 106:378-82. PubMed
  • Hong TS, Wo JY, Kwak EL. Targeted therapies with chemoradiation in esophageal cancer: development and future directions. Semin Radiat Oncol 2012; 23:31-7. PubMed
  • Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS, Enzinger PC. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist 2013; 18:281-7. PubMed
  • Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist 2013. PubMed
  • Hartman RI, Chang CY, Wo JY, Eisenberg JD, Hong TS, Harisinghani MG, Gazelle GS, Pandharipande PV. Optimizing adjuvant treatment decisions for stage t2 rectal cancer based on mesorectal node size: a decision analysis. Acad Radiol 2012. PubMed
  • Kleiman LB, Krebs AM, Kim SY, Hong TS, Haigis KM. Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers. PLoS ONE 2013; 8:e82982. PubMed
  • Chin JY, Hong TS, Ryan DP. Mitomycin in anal cancer: still the standard of care. J Clin Oncol 2012. PubMed
  • Phillips JG, Hong TS, Ryan DP. Multidisciplinary management of early-stage rectal cancer. J Natl Compr Canc Netw 2012; 10:1577-85. PubMed
  • Wo JY, Hong TS, Kachnic LA. Impact of age and comorbidities on the treatment of gastrointestinal malignancies. Semin Radiat Oncol 2012; 22:311-20. PubMed
  • Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, Allen JN, Clark JW, Wadlow RC, Zhu AX, Fernandez-Del Castillo C, Hong TS. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer 2012. PubMed
  • Hallman JL, Mori S, Sharp GC, Lu HM, Hong TS, Chen GT. A four-dimensional computed tomography analysis of multiorgan abdominal motion. Int J Radiat Oncol Biol Phys 2012. PubMed
  • Adkison JB, McHaffie DR, Bentzen SM, Patel RR, Khuntia D, Petereit DG, Hong TS, Tomé W, Ritter MA. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2011; 82:184-90. PubMed
  • Craft DL, Hong TS, Shih HA, Bortfeld TR. Improved planning time and plan quality through multicriteria optimization for intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2011; 82:e83-90. PubMed
  • Jones WE, Thomas CR, Herman JM, Abdel-Wahab M, Azad N, Blackstock W, Das P, Goodman KA, Hong TS, Jabbour SK, Konski AA, Koong AC, Rodriguez-Bigas M, Small W, Zook J, Suh WW. ACR appropriateness criteria®  resectable rectal cancer. Radiat Oncol 2012; 7:161. PubMed
  • Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, Clark J, Willett CG, Hong TS. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys 2011. PubMed
  • Knopf AC, Hong TS, Lomax A. Scanned proton radiotherapy for mobile targets-the effectiveness of re-scanning in the context of different treatment planning approaches and for different motion characteristics. Phys Med Biol 2011; 56:7257-71. PubMed
  • Engelsman M, DeLaney TF, Hong TS. Proton radiotherapy: the biological effect of treating alternating subsets of fields for different treatment fractions. Int J Radiat Oncol Biol Phys 2011; 79:616-22. PubMed
  • Hong TS, Ryan DP, Blaszkowsky LS, Mamon HJ, Kwak EL, Mino-Kenudson M, Adams J, Yeap B, Winrich B, Delaney TF, Fernandez-Del Castillo C. Phase I Study of Preoperative Short-Course Chemoradiation with Proton Beam Therapy and Capecitabine for Resectable Pancreatic Ductal Adenocarcinoma of the Head. Int J Radiat Oncol Biol Phys 2010; 79:151-7. PubMed
  • Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, Willins JD, Ryan DP, Hong TS. Dose-painted Intensity-modulated Radiation Therapy for Anal Cancer: A Multi-institutional Report of Acute Toxicity and Response to Therapy. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Mak RH, McCarthy EP, Das P, Hong TS, Mamon HJ, Hoffman KE. Adoption of Preoperative Radiation Therapy for Rectal Cancer From 2000 to 2006: A Surveillance, Epidemiology, and End Results Patterns-of-Care Study. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Klos CL, Shellito PC, Rattner DW, Hodin RA, Cusack JC, Bordeianou L, Sylla P, Hong TS, Blaszkowsky L, Ryan DP, Lauwers GY, Chang Y, Berger DL. The effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes after rectal cancer surgery. Am J Surg 2010; 200:440-5. PubMed
  • Arvold ND, Niemierko A, Mamon HJ, Fernandez-Del Castillo C, Hong TS. Pancreatic Cancer Tumor Size on CT Scan Versus Pathologic Specimen: Implications for Radiation Treatment Planning. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Miyamoto DT, Mamon HJ, Ryan DP, Willett CG, Ancukiewicz M, Kobayashi WK, Blaszkowsky L, Castillo CF, Hong TS. Outcomes and Tolerability of Chemoradiation Therapy for Pancreatic Cancer Patients Aged 75 Years or Older. Int J Radiat Oncol Biol Phys 2010; 77:1171-7. PubMed
  • Chen RC, Mamon HJ, Chen YH, Gelman RS, Suh WW, Talcott JA, Clark JW, Hong TS. Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer. Cancer 2010; 116:1879-86. PubMed
  • Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, Niemierko A, Wolfgang JA, Lu HM, Adams J, Weyman EA, Arellano RS, Blaszkowsky LS, Allen JN, Tanabe KK, Ryan DP, Zhu AX. A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. 2014; 4:316-22. PubMed
  • Wo JY, Childs SK, Szymonifka J, Mamon HJ, Ryan DP, Blaszkowsky LS, Kwak EL, Ferrone CR, Allen JN, Zhu AX, Wolpin BM, Chan JA, Abrams TA, McCleary NJ, Fernandez-del Castillo C, Hong TS. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. 2014; 4:e117-23. PubMed
  • Jabbour SK, Hashem SA, Bosch W, Kim TK, Finkelstein SE, Anderson BM, Ben-Josef E, Crane CH, Goodman KA, Haddock MG, Herman JM, Hong TS, Kachnic LA, Mamon HJ, Pantarotto JR, Dawson LA. Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus. 2014; 4:82-9. PubMed
  • Yoon SS, Aloia TA, Haynes AB, Kambadakone A, Kaur H, Vauthey JN, Ferrone CR, Zhu AX, Wo JY, Crane C, Hong TS. Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy. 2014; 4:167-73. PubMed
Hide